Huddleston Hailey P, Kurtzman Joey S, Gedailovich Samuel, Koehler Steven M, Aibinder William R
SUNY Downstate Medical Center, Department of Orthopaedic Surgery and Rehabilitation Medicine, Brooklyn, NY, 11203, USA.
J Orthop. 2021 Nov 24;28:70-85. doi: 10.1016/j.jor.2021.11.014. eCollection 2021 Nov-Dec.
The purpose of this systematic review was to (1) define the cumulative humerus fracture rate after BT and (2) compare how often fracture rate was reported compared to other complications.
A systematic review was performed using the PRISMA guidelines.
39 studies reported complications and 30 reported no complications. Of the 39 studies that reported complications, 5 studies reported fracture after BT (n = 669, cumulative incidence of 0.53%). The overall non-fracture complication rate was 12.9%.
Due to the relatively high incidence of fracture, surgeons should ensure that this complication is disclosed to patients undergoing BT.
本系统评价的目的是(1)确定肉毒毒素(BT)治疗后肱骨骨折的累积发生率,以及(2)比较与其他并发症相比,骨折发生率的报告频率。
采用PRISMA指南进行系统评价。
39项研究报告了并发症,30项研究报告无并发症。在报告并发症的39项研究中,5项研究报告了BT治疗后发生骨折(n = 669,累积发生率为0.53%)。总体非骨折并发症发生率为12.9%。
由于骨折发生率相对较高,外科医生应确保向接受BT治疗的患者披露这一并发症。